Gilead Sciences Q1 EPS Forecast Increased by Zacks Research

Gilead Sciences, Inc. (NASDAQ:GILD) – Zacks Research boosted their Q1 2025 earnings per share estimates for shares of Gilead Sciences in a note issued to investors on Monday, November 4th. Zacks Research analyst E. Bagri now anticipates that the biopharmaceutical company will post earnings of $1.63 per share for the quarter, up from their prior estimate of $1.62. The consensus estimate for Gilead Sciences’ current full-year earnings is $3.75 per share. Zacks Research also issued estimates for Gilead Sciences’ Q3 2025 earnings at $2.04 EPS, Q4 2025 earnings at $1.80 EPS, Q1 2026 earnings at $1.62 EPS and Q3 2026 earnings at $2.11 EPS.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.61 by $0.40. The company had revenue of $6.95 billion for the quarter, compared to analyst estimates of $6.64 billion. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%.

Other equities analysts have also recently issued reports about the company. Leerink Partnrs upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 21st. Piper Sandler reiterated an “overweight” rating and set a $95.00 price target on shares of Gilead Sciences in a research report on Wednesday, September 11th. BMO Capital Markets raised their price objective on shares of Gilead Sciences from $85.00 to $94.00 and gave the company an “outperform” rating in a research report on Thursday, October 17th. Barclays upped their target price on shares of Gilead Sciences from $76.00 to $84.00 and gave the stock an “equal weight” rating in a report on Monday, October 7th. Finally, Cantor Fitzgerald reissued a “neutral” rating and issued a $70.00 price target on shares of Gilead Sciences in a report on Monday, September 16th. Ten equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $86.85.

Gilead Sciences Stock Up 1.6 %

Gilead Sciences stock opened at $91.69 on Wednesday. The firm has a 50 day simple moving average of $84.58 and a 200 day simple moving average of $74.67. The company has a current ratio of 1.14, a quick ratio of 0.95 and a debt-to-equity ratio of 1.18. Gilead Sciences has a 1-year low of $62.07 and a 1-year high of $91.98. The firm has a market capitalization of $114.15 billion, a price-to-earnings ratio of 111.82, a P/E/G ratio of 3.12 and a beta of 0.17.

Hedge Funds Weigh In On Gilead Sciences

A number of hedge funds have recently modified their holdings of GILD. GSA Capital Partners LLP bought a new position in Gilead Sciences during the 1st quarter valued at approximately $462,000. Larson Financial Group LLC lifted its stake in Gilead Sciences by 22.7% in the first quarter. Larson Financial Group LLC now owns 1,493 shares of the biopharmaceutical company’s stock worth $109,000 after acquiring an additional 276 shares during the period. Mediolanum International Funds Ltd purchased a new stake in Gilead Sciences in the first quarter worth $4,592,000. Catalina Capital Group LLC bought a new stake in Gilead Sciences in the first quarter valued at $204,000. Finally, SPC Financial Inc. increased its position in Gilead Sciences by 10.5% during the 1st quarter. SPC Financial Inc. now owns 4,212 shares of the biopharmaceutical company’s stock valued at $309,000 after purchasing an additional 400 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Activity

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total transaction of $167,660.00. Following the completion of the sale, the insider now directly owns 100,189 shares in the company, valued at $8,398,843.87. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, insider Johanna Mercier sold 29,357 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the transaction, the insider now owns 78,127 shares in the company, valued at approximately $6,545,480.06. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total transaction of $167,660.00. Following the sale, the insider now owns 100,189 shares of the company’s stock, valued at $8,398,843.87. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 36,847 shares of company stock valued at $3,033,340. Corporate insiders own 0.29% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.